BACKGROUND: We report our experience in the elderly with aortic valve replacement using the Mitroflow A12 pericardial bioprosthesis. METHODS: From January 1993 to January 2006, 491 patients over the age of 70 years received an aortic Mitroflow A12 bioprosthesis implantation. Concomitant procedures included coronary artery bypass grafting in 20% of patients. All patients had routine postoperative Echo-Doppler studies at discharge, one month and a mean of 11.1 months after surgery and annually thereafter. RESULTS: Twenty (4%) patients underwent a second aortic valve replacement due to bioprosthetic valve dysfunction (Group 2). Calcified stenosis was the most common finding at reoperation (98%). Median time to valve reoperation was 76 months. Of patients requiring reoperation, median age at first and second implantation was 73 (70-78) and 79 (76-83) years, respectively. For all patients, freedom from structural valve dysfunction (SVD) was 95+/-3% at 5 years and 55.8+/-2% at 10 years. Bioprosthetic valve deterioration was identified in 27 patients (Group 1). Median age of these patients at first operation and at diagnosis of deterioration by echo was 75 (70-84) and 77 (70-82) years, respectively. The median interval between operation and detection of bioprosthesis valve deterioration was 46 months. Among the total patient population, freedom from bioprosthetic deterioration was 85.7+/-2% at 5 years and 33.5+/-4% at 10 years. CONCLUSION: The Mitroflow A12 pericardial bioprosthesis provides less than optimal performance in elderly patients.
BACKGROUND: We report our experience in the elderly with aortic valve replacement using the Mitroflow A12 pericardial bioprosthesis. METHODS: From January 1993 to January 2006, 491 patients over the age of 70 years received an aortic Mitroflow A12 bioprosthesis implantation. Concomitant procedures included coronary artery bypass grafting in 20% of patients. All patients had routine postoperative Echo-Doppler studies at discharge, one month and a mean of 11.1 months after surgery and annually thereafter. RESULTS: Twenty (4%) patients underwent a second aortic valve replacement due to bioprosthetic valve dysfunction (Group 2). Calcified stenosis was the most common finding at reoperation (98%). Median time to valve reoperation was 76 months. Of patients requiring reoperation, median age at first and second implantation was 73 (70-78) and 79 (76-83) years, respectively. For all patients, freedom from structural valve dysfunction (SVD) was 95+/-3% at 5 years and 55.8+/-2% at 10 years. Bioprosthetic valve deterioration was identified in 27 patients (Group 1). Median age of these patients at first operation and at diagnosis of deterioration by echo was 75 (70-84) and 77 (70-82) years, respectively. The median interval between operation and detection of bioprosthesis valve deterioration was 46 months. Among the total patient population, freedom from bioprosthetic deterioration was 85.7+/-2% at 5 years and 33.5+/-4% at 10 years. CONCLUSION: The Mitroflow A12 pericardial bioprosthesis provides less than optimal performance in elderly patients.
Authors: Jose Manuel Martinez Cereijo; Jose Rubio Alvarez; Juan Sierra Quiroga; Anxo Martinez de Alegria; Jose Manuel Suarez Peñaranda Journal: J Cardiothorac Surg Date: 2010-10-07 Impact factor: 1.637
Authors: José Manuel Martínez-Comendador; Francisco Estevez-Cid; Miguel González Barbeito; Carlos Velasco García De Sierra; Alberto Bouzas Mosquera; Cayetana Barbeito; José Cuenca Castillo; José Herrera-Noreña Journal: Interact Cardiovasc Thorac Surg Date: 2021-04-19
Authors: Suengwon Lee; Robert J Levy; Abigail J Christian; Stanley L Hazen; Nathan E Frick; Eric K Lai; Juan B Grau; Joseph E Bavaria; Giovanni Ferrari Journal: J Am Heart Assoc Date: 2017-05-08 Impact factor: 5.501